NCT04741997 - Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 24, 2021

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

Melanoma Stage IIIMelanoma Stage IVBRAF V600 Mutation

Interventions

DRUG

Encorafenib Pill

Encorafenib 450 mg will be administered orally once per day in continuous 28-day cycles

DRUG

Binimetinib Pill

Binimetinib 45 mg will be administered orally twice per day in continuous 28-day cycles

DRUG

Nivolumab

Nivolumab will be administered at a dose of 480 mg IV infusion over 30 minutes every 4 weeks.

Trial Locations (1)

RECRUITING

Moffitt Cancer Center, Tampa